HCV Antigen Profiling for Broadly Neutralizing Antibody Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of an effective hepatitis C virus (HCV) vaccine is hindered by the incomplete understanding of protective immunity correlates and inadequate methods for assessing antibody responses, particularly the antigenic stimuli required to induce broadly neutralizing antibodies (bNAbs) in humans, and the genetic diversity of the virus poses challenges.
Innovation Solution
Methods are developed to identify antigenic profiles of hepatitis viruses by measuring plasma antibody neutralization, deconvoluting neutralizing antibodies, and defining antigenic profiles associated with increased breadth and potency, using pseudoviral particles and neutralization assays to select vaccine antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional vaccine development approaches are used, then the development process is simplified, but the ability to identify antigenic stimuli that induce broadly neutralizing antibodies is insufficient
Solution Approach 1:
The patent segments the complex assessment of antibody responses into distinct modular components: pseudoviral particle neutralization assays, deconvolution algorithms, and antigenic cartography. This segmentation enables precise identification of antigenic stimuli while maintaining manageable complexity through systematic breakdown of the assessment process.
Solution Approach 2:
The patent introduces pseudoviral particles as an intermediary system to assess neutralizing antibody responses. These particles serve as a controlled mediator between the antibody responses and the virus, enabling precise measurement of neutralization without direct exposure to complex viral systems, thereby improving measurement precision while controlling complexity.
2Measurement precision
If comprehensive neutralization assays are conducted to identify bNAbs, then the precision of identifying protective immunity correlates is improved, but the time and resources required increase
Solution Approach 1:
The patent employs preliminary action by using deconvolution algorithms to predict antigenic profiles and identify potential bNAbs before conducting full-scale neutralization assays. This preliminary computational analysis filters and prioritizes candidates, enabling more efficient subsequent experimental validation and reducing overall development time while maintaining precision.
Solution Approach 2:
The patent substitutes mechanical and computational systems by implementing deconvolution algorithms and antigenic cartography that computationally analyze neutralization data. This replacement of manual analysis with automated computational methods accelerates the identification of protective immunity correlates without sacrificing precision, significantly reducing the time required for comprehensive assessment.
3Reliability
If pseudoviral particles are used to assess neutralization, then the safety and control of assays are improved, but the complexity of generating and characterizing these particles increases
Solution Approach 1:
The patent extracts the essential neutralization assessment function from complex whole-virus systems by using pseudoviral particles that contain only the necessary envelope proteins. This extraction maintains assay safety and control by removing harmful viral components while retaining the ability to assess neutralizing responses, and the standardized particle generation protocols manage the complexity of production.
Data Source
AI summary
Methods of identifying virus antigens are provided. In particular the antigens induce broadly neutralizing antibodies in Hepatitis C virus infections. Compositions for inducing an immune response are identified by the methods described herein.